Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Rating of “Hold” from Brokerages

Fractyl Health, Inc. (NASDAQ:GUTS) has earned a consensus recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $5.40.

A number of research firms have recently commented on GUTS. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Finally, Morgan Stanley lowered shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $8.00 to $2.00 in a report on Thursday, January 29th.

Hedge Funds Weigh In On Fractyl Health

A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Fractyl Health during the 2nd quarter valued at $31,000. FNY Investment Advisers LLC acquired a new stake in Fractyl Health in the 3rd quarter valued at $31,000. Scientech Research LLC acquired a new stake in Fractyl Health in the 3rd quarter valued at $49,000. Prelude Capital Management LLC purchased a new position in Fractyl Health in the third quarter valued at about $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Fractyl Health in the third quarter valued at about $56,000.

Fractyl Health Trading Up 7.2%

GUTS stock opened at $0.46 on Friday. The company has a market cap of $72.63 million, a price-to-earnings ratio of -0.25 and a beta of 1.51. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 3.23. The business has a fifty day simple moving average of $0.65 and a 200-day simple moving average of $1.27. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.34. On average, equities research analysts expect that Fractyl Health will post -1.61 EPS for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.